Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 15Esophageal Neoplasms 9Melanoma 6Lung Neoplasms 6Colorectal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Small Cell Lung Carcinoma 4Esophageal Squamous Cell Carcinoma 4Carcinoma, Hepatocellular 4Stomach Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Uterine Cervical Neoplasms 2Neoplasms 2Nasopharyngeal Carcinoma 2Carcinoma, Transitional Cell 2Unresectable Biliary Tract Cancer 1Thymus Neoplasms 1Thymoma 1Thymic epithelial tumor 1Small Cell Lung Cancer Extensive Stage 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1Pathologic Complete Response 1Neuroblastoma 1Neoplasms, Germ Cell and Embryonal 1Nasopharyngeal Neoplasms 1Muscle-Invasive Bladder Carcinoma 1

Interventions

Carboplatin 4pertuzumab 2durvalumab 2Tretinoin 2Trastuzumab 2Standard of Care 2Paclitaxel 2Oxaliplatin 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1toripalimab 1tislelizumab 1talazoparib 1sarilumab 1relugolix 1regorafenib 1pexidartinib 1pembrolizumab 1patritumab 1olaparib 1niraparib 1nimotuzumab 1neratinib 1ganitumab 1enzalutamide 1dostarlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Pathologic Complete Response × Immunotherapy × Clear all
NCT06811844 2025-07-01

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

The First Affiliated Hospital of Xiamen University

Phase 2 Recruiting
208 enrolled
Head & Neck

Pathologic Complete Response, Nasopharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡